Oral Micronized Progesterone Pharmacokinetics (ADME)

What Is Oral Micronized Progesterone and Why Does Particle Size Matter?

Micronization reduces progesterone crystals to particles smaller than 10 micrometers, which dramatically increases the surface area available for dissolution in gastrointestinal fluids. Without this step, oral progesterone is essentially insoluble and clinically inactive.

Prometrium suspends these micro-particles in a peanut-oil and gelatin capsule matrix. That lipid vehicle is not cosmetic. Fat-soluble steroids require bile-salt-facilitated micelle formation for mucosal uptake, and the presence of dietary or vehicle fat directly drives micellar solubilization of progesterone at the intestinal brush border. A 2001 pharmacokinetic study by Simon et al. Quantified this: Cmax rose from roughly 17 ng/mL in fasted women to 53 ng/mL when the same 200 mg dose was taken with food, a 3.1-fold increase (1).

Why Standard Crystalline Progesterone Fails Orally

Before micronization, crystalline progesterone in oral tablets produced serum levels indistinguishable from placebo. The molecule's log P of approximately 3.87 makes it highly lipophilic, which is paradoxically both its solubility problem in aqueous gut fluid and its advantage once incorporated into lipid micelles. Micronization solves the dissolution step without altering the molecule's chemistry.

Clinical Implications of the Food Effect

Because food raises absorption 3-fold, prescribers at HealthRX instruct patients to take Prometrium with the largest meal of the day or at bedtime after a snack. Patients who take it on an empty stomach may report insufficient symptom control not because the dose is wrong but because absorption is blunted. This distinction matters before any dose escalation.

Absorption: Gastrointestinal Uptake and First-Pass Extraction

Oral micronized progesterone is absorbed primarily in the small intestine via passive transcellular diffusion. Absolute bioavailability after a 200 mg oral dose is approximately 10%, reflecting extensive first-pass extraction by both intestinal enterocytes and hepatocytes (2).

Tmax and Cmax in Practice

After a 200 mg dose taken with food, mean Cmax reaches 17 to 60 ng/mL (wide range due to inter-individual CYP variability) at a Tmax of 1 to 3 hours. Fasting Cmax averages 14 to 17 ng/mL. These values contrast with the luteal-phase endogenous peak of 5 to 20 ng/mL, meaning therapeutic oral dosing can transiently exceed physiological luteal concentrations before rapid redistribution pulls serum levels down.

Dose Linearity

Pharmacokinetics are roughly dose-proportional between 100 mg and 300 mg, though Cmax and AUC scale with slightly less than perfect linearity at higher doses, likely because saturation of micellar capacity limits per-molecule uptake at a fixed lipid vehicle volume. The FDA label for Prometrium reports a Cmax of 17.3 ng/mL (±21.9 SD) for the 100 mg dose and 38.1 ng/mL (±37.8 SD) for the 300 mg dose in postmenopausal women after a high-fat meal (3).

Inter-Patient Variability

Coefficient of variation for Cmax exceeds 50% in most studies. Body weight, gut transit time, bile-acid secretory capacity, and CYP2C19 genotype all contribute. This variability is one reason serum progesterone assays are occasionally useful to confirm adequate absorption rather than defaulting immediately to dose increases.

Distribution: Volume, Protein Binding, and Tissue Penetration

Once absorbed, progesterone distributes rapidly into tissues. The apparent volume of distribution after intravenous administration is approximately 44 L/kg, reflecting avid uptake into adipose tissue, the central nervous system, and steroid-target tissues including the uterus, breast, and brain (4).

Plasma Protein Binding

More than 96% of circulating progesterone is protein-bound, primarily to:

• Corticosteroid-binding globulin (CBG, transcortin): high-affinity, saturable binding
• Albumin: lower affinity but high-capacity binding

Only the free fraction, under 4%, is pharmacologically active at progesterone receptors (PR-A and PR-B). Conditions that reduce CBG concentration, such as liver disease or high-dose estrogen therapy, may increase free-progesterone fraction and amplify pharmacodynamic effects at a given total serum concentration.

CNS Penetration and the Neurosteroid Pool

Progesterone crosses the blood-brain barrier readily due to its lipophilicity. Brain concentrations after oral dosing may exceed plasma concentrations because the brain also synthesizes progesterone locally (neurosteroidogenesis) and concentrates it from the circulation. This CNS distribution is clinically relevant: the sedative and anxiolytic effects of oral progesterone depend partly on direct receptor-mediated activity and partly on local conversion to GABA-A-active metabolites within neural tissue.

Metabolism: First-Pass, Hepatic, and Neurosteroid Pathways

Metabolism is the pharmacokinetic step that most distinguishes oral micronized progesterone from vaginal or transdermal routes. Oral dosing forces the drug through the splanchnic circulation before reaching systemic blood, generating large quantities of metabolites that have independent pharmacological activity.

Hepatic Phase I Metabolism

The liver is the primary metabolic site. Two cytochrome P450 enzymes dominate:

CYP2C19 catalyzes 6-beta-hydroxylation and C-16 oxidation. CYP2C19 poor metabolizers (approximately 2 to 3% of White and Black populations, 15 to 20% of East Asian populations) show substantially higher progesterone exposure and may be more prone to sedation at standard doses (5).

CYP3A4 handles additional hydroxylation steps. CYP3A4 inducers such as rifampin, carbamazepine, and St. John's Wort may reduce progesterone exposure significantly, a real concern in patients on epilepsy regimens who also receive HRT.

Beyond P450 oxidation, aldo-keto reductases (AKR1C1, AKR1C4) and 5-alpha/5-beta reductases convert progesterone to a series of reduced pregnane metabolites:

• 5-alpha-pregnane-3,20-dione (5-alpha-dihydroprogesterone, 5a-DHP)
• Allopregnanolone (3-alpha-hydroxy-5-alpha-pregnan-20-one, ALLO)
• Pregnanolone (3-alpha-hydroxy-5-beta-pregnan-20-one)
• 20-alpha-dihydroprogesterone (20a-DHP)

Allopregnanolone: The Clinically Active Neurosteroid

Allopregnanolone is the metabolite most responsible for the sedative, anxiolytic, and sleep-promoting properties of oral progesterone. It is a potent positive allosteric modulator of GABA-A receptors, binding at the same site as benzodiazepines and neurosteroid anesthetics. In a 2003 crossover study by Andreen et al., oral progesterone 200 mg raised serum allopregnanolone levels 10-fold compared to placebo, correlating with subjective sedation scores and EEG slow-wave activity (6).

This is why oral progesterone is preferentially prescribed at bedtime in most HealthRX protocols, and it also explains why vaginal progesterone, which bypasses first-pass metabolism, produces minimal sedation at equivalent uterine-protective doses: allopregnanolone generation depends entirely on hepatic first-pass conversion.

Phase II Conjugation and Biliary Excretion

Phase I metabolites undergo glucuronidation (UGT enzymes, primarily UGT2B7 and UGT1A4) and sulfation (SULT2A1) to form water-soluble conjugates. These conjugates exit hepatocytes into bile, pass into the intestinal lumen, and may undergo enterohepatic recirculation via bacterial deconjugation in the colon followed by reabsorption. This recycling contributes to the prolonged terminal half-life of 16 to 18 hours despite a short initial distribution half-life of approximately 6 hours (2).

Excretion: Renal, Biliary, and Enterohepatic Recycling

Greater than 50% of an administered oral progesterone dose is excreted in urine as glucuronide conjugates of pregnanediol (primarily pregnanediol-3-glucuronide, PDG) and other reduced metabolites. Less than 1% appears as unchanged progesterone in urine, confirming near-complete presystemic and systemic extraction (3).

Renal Considerations

No dose adjustment is specified in the Prometrium label for renal impairment, because the drug itself is minimally renally cleared. However, accumulation of glucuronide conjugates could theoretically occur in severe renal disease. Clinicians should monitor patients with estimated GFR <30 mL/min/1.73m² for signs of enhanced sedation, as conjugate accumulation and potential back-hydrolysis could increase active metabolite exposure.

Hepatic Impairment

Hepatic metabolism is so dominant that moderate to severe liver disease would be expected to reduce first-pass extraction, paradoxically increasing systemic progesterone bioavailability, while simultaneously reducing conversion to allopregnanolone and other Phase I products. This creates an unpredictable pharmacokinetic profile. The Prometrium label lists hepatic dysfunction as a contraindication for this reason (3).

Fecal Excretion

Biliary-excreted conjugates that escape intestinal reabsorption account for roughly 10% of total elimination via feces. The fraction subject to enterohepatic recirculation is not precisely quantified in humans but likely contributes to the secondary Cmax peak (a shallow second rise in serum progesterone) sometimes visible 6 to 8 hours post-dose in dense pharmacokinetic sampling studies.

Half-Life and Dosing Interval Implications

The terminal half-life of 16 to 18 hours supports once-daily dosing for endometrial protection. Accumulation at steady state is modest: after 4 to 5 days of nightly 200 mg dosing, trough serum progesterone levels stabilize at 2 to 6 ng/mL in most patients, within or slightly above the early luteal range of 1 to 5 ng/mL (1).

PEPI Trial Context

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial (N=875, JAMA 1995) randomized postmenopausal women to conjugated equine estrogen alone or with medroxyprogesterone acetate (MPA) or micronized progesterone 200 mg/day cyclic. The micronized progesterone arm showed endometrial protection equivalent to MPA, with a hyperplasia rate of 1% vs. 62% in the unopposed estrogen group at 3 years. The MPA arm and micronized progesterone arm were statistically indistinguishable for endometrial outcomes. The progesterone arm also showed a more favorable HDL-cholesterol profile than MPA, with HDL falling 1.6 mg/dL vs. 4.1 mg/dL with MPA (P<0.001) (7).

The Endocrine Society's 2015 Clinical Practice Guideline on postmenopausal hormone therapy states: "Micronized progesterone and dydrogesterone appear to have a more favorable safety profile than synthetic progestins with respect to breast cancer risk and cardiovascular outcomes," directly reflecting pharmacokinetic and receptor-selectivity differences from MPA (8).

Why Nightly Dosing Maximizes Benefit

Concentrating peak allopregnanolone exposure during sleep aligns pharmacokinetics with clinical goals: the sedative metabolite spike at 1 to 3 hours aids sleep onset while uterotrophic progesterone receptor activation persists through the night and into the next morning via the 16 to 18 hour elimination tail. Splitting the dose (e.g., 100 mg morning, 100 mg night) would theoretically maintain more stable serum progesterone but sacrifices the sleep benefit and may reduce peak uterine receptor saturation.

Oral vs. Vaginal vs. Transdermal: Pharmacokinetic Comparisons

Route of administration determines which compartment receives the highest progesterone exposure, and this shapes both efficacy and tolerability.

Oral Route

Delivers high hepatic exposure, generates abundant neurosteroid metabolites, and provides systemic progesterone for endometrial protection. Produces measurable serum progesterone. The trade-off is first-pass extraction, which means oral doses must be 10 to 20x higher than parenteral doses to achieve equivalent systemic exposure.

Vaginal Route

The uterine first-pass effect (also called the "first-uterine-pass effect") concentrates progesterone in the endometrium via the venous drainage from the vaginal wall into the uterine vasculature. Vaginal progesterone 90 mg gel produces endometrial concentrations sufficient for luteal support in IVF while yielding serum progesterone levels of only 4 to 8 ng/mL, far below what an equivalent oral dose would produce. Neurosteroid metabolite generation is proportionally low, explaining the minimal sedation with vaginal formulations (9).

Transdermal Route

Cream and gel preparations applied to skin bypass both hepatic first-pass and intestinal metabolism. Serum progesterone levels after transdermal progesterone creams are generally 1 to 3 ng/mL, and there is ongoing debate about whether these levels are sufficient for endometrial protection in women on estrogen therapy. A 2005 study by Wren et al. Found no significant endometrial protection with transdermal progesterone cream vs. Placebo over 48 weeks (10).

Drug Interactions Affecting Oral Progesterone Pharmacokinetics

CYP3A4 and CYP2C19 Inducers

Rifampin, phenytoin, carbamazepine, and St. John's Wort are strong CYP3A4 inducers that may reduce oral progesterone AUC by 50% or more. Patients on these agents receiving oral progesterone for endometrial protection may have inadequate progestogenic coverage. Serum progesterone monitoring and consideration of alternative progestogen routes is warranted.

CYP3A4 Inhibitors

Azole antifungals (ketoconazole, itraconazole) and certain HIV protease inhibitors may increase progesterone exposure. The clinical consequence in HRT patients is likely increased sedation rather than toxicity, but the prescriber should be aware.

Estrogen Co-administration

Oral estradiol raises CBG concentrations, which could reduce free progesterone fraction. Whether this affects endometrial protection is uncertain, but it provides one mechanistic reason why some clinicians prefer slightly higher progesterone doses (300 mg/day) in patients on high-dose oral estradiol.

Pharmacokinetic Parameters: Summary Table

| Parameter | Value (Oral, 200 mg with food) | Source | |---|---|---| | Bioavailability | ~10% (range 5 to 20%) | FDA label | | Tmax | 1.5 to 3 hours | Simon et al. 2001 | | Cmax (200 mg, fed) | 38 to 60 ng/mL (high variability) | FDA label | | Volume of distribution | ~44 L/kg (IV reference) | Fotherby 1996 | | Protein binding | >96% | FDA label | | Half-life (terminal) | 16 to 18 hours | Nahoul et al. | | Primary metabolites | Allopregnanolone, pregnanolone, PDG | Andreen et al. 2003 | | Primary elimination route | Renal (glucuronide conjugates) | FDA label | | Unchanged urinary excretion | <1% | FDA label |

Clinical Takeaways for Prescribers

Oral micronized progesterone pharmacokinetics shape every practical decision in HRT prescribing. Four points recur most often in clinical management:

Administer with food or at bedtime after a snack. The 3-fold food effect is large enough to convert a subtherapeutic exposure into an adequate one. This single instruction resolves a substantial proportion of "progesterone isn't working" complaints.

Expect sedation at 1 to 3 hours. Allopregnanolone peaks coincide with Tmax. Scheduling the dose at bedtime converts a side effect into a benefit for patients with HRT-associated sleep disruption.

Check CYP2C19 genotype in patients with unusual sensitivity or resistance. Poor metabolizers accumulate progesterone and show exaggerated sedation; ultra-rapid metabolizers may need higher doses or route switching.

Do not use oral progesterone in patients with hepatic dysfunction. Metabolism is so hepatic-dependent that the route effectively becomes unpredictable when liver enzyme systems are compromised.

The PEPI trial data showing endometrial hyperplasia rates of 1% with micronized progesterone 200 mg at 3 years, combined with the pharmacokinetic profile showing steady-state trough levels within the luteal range after once-daily dosing, confirms that 200 mg nightly is the minimum effective dose for continuous endometrial protection in women receiving systemic estrogen (7).